Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

  • Revenue in USD (TTM)38.90bn
  • Net income in USD13.62bn
  • Incorporated1931
  • Employees71.88k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NOVO B:CPH since
announced
Transaction
value
Cardior Pharmaceuticals GmbHAnnounced25 Mar 202425 Mar 2024Announced-15.95%1.11bn
Catalent Inc-Manufacturing Sites Portfolio(3)Announced05 Feb 202405 Feb 2024Announced-4.57%--
Elan Drug Technologies (DNU>16Sep2011 now 01781A)Announced14 Dec 202314 Dec 2023Announced11.00%92.42m
Data delayed at least 15 minutes, as of Nov 08 2024 15:59 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Merck & Co Inc63.17bn12.15bn260.35bn72.00k21.585.8615.854.124.774.7724.9517.580.56342.395.80877,416.7010.857.7014.1910.2976.5972.2619.2515.031.1524.330.461189.551.407.29-97.49-43.808.128.26
AbbVie Inc55.53bn5.08bn352.54bn50.00k69.6058.4426.096.352.872.8731.323.410.39724.314.851,110,660.003.676.555.098.4067.2569.749.2416.460.54197.880.9213111.46-6.4410.65-59.09-3.444.0210.52
Novo Nordisk A/S (ADR)38.90bn13.62bn366.23bn71.88k35.1727.3324.549.423.053.058.713.920.77581.234.55613,825.3027.1629.1759.8358.6284.6683.9335.0133.550.7546--0.32150.1331.2615.7450.7116.7225.6710.97
Johnson & Johnson87.70bn14.77bn374.31bn131.90k25.565.3316.974.276.086.0536.1229.140.50942.275.66664,867.308.588.9311.9011.9669.1668.1716.8418.860.7853--0.337671.256.460.8622-18.59-2.724.365.83
Data as of Nov 09 2024. Currency figures normalised to Novo Nordisk A/S's reporting currency: US Dollar USD

Institutional shareholders

3.28%Per cent of shares held by top holders
HolderShares% Held
Jennison Associates LLCas of 30 Jun 202421.22m0.63%
Fidelity Management & Research Co. LLCas of 30 Jun 202414.55m0.43%
Fisher Asset Management LLCas of 30 Jun 202413.37m0.39%
Fayez Sarofim & Co.as of 30 Jun 202412.55m0.37%
Renaissance Technologies LLCas of 30 Jun 20249.17m0.27%
Loomis, Sayles & Co. LPas of 30 Jun 20248.90m0.26%
Folketrygdfondetas of 30 Jun 20248.84m0.26%
Managed Account Advisors LLCas of 30 Jun 20248.11m0.24%
Polen Capital Management LLCas of 30 Jun 20247.45m0.22%
Capital Research & Management Co. (International Investors)as of 30 Jun 20246.96m0.21%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.